NCT01381458View on ClinicalTrials.gov

Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation

CompletedOBSERVATIONAL
Enrollment

1,936

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

March 31, 2011

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

FSC

fluticasone propionate / salmeterol xinofoate combination

DRUG

ACs

tiotropium alone, ipratropium alone, or in combination with albuterol

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01381458 - Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation | Biotech Hunter | Biotech Hunter